New drug DAOIB hopes to clear long COVID brain fog

NCT ID NCT05764538

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a drug called DAOIB in 40 people with Long COVID who have memory and thinking problems (brain fog). Everyone gets the drug for 24 weeks, and researchers check their thinking skills, mood, and quality of life every 8 weeks. The goal is to see if DAOIB can help improve cognitive function.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
DAOIB (a drug)
What this could lead to
If it works, this could point toward a treatment for brain fog and other cognitive problems caused by Long COVID.
What could go wrong
This is a small, early-phase trial with only 40 people and no placebo group, so results may not be reliable. The drug may not work or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LONG COVID are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Kaohsiung Chang Gung Memorial Hospital

    RECRUITING

    Kaohsiung City, 886, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.